Valeant Continues to Grow by Acquisition

By Bizclik Editor

 

Valeant Pharmaceuticals and its subsidiaries announced today that it has signed an agreement to acquire Ortho Dermatologics division of Janssen Pharmaceuticals. Valued at $345 million, Valeant will pay Janssen for its assets.

Janssen’s Ortho Dermatologics division has a widely known portfolio including prescription brands RETIN-A MICRO ®, ERTACZO ®, and RENOVA ®. In 2010, the portfolio was valued at $150 million. The agreement is still subject to closing conditions and regulatory approvals.

"With the combination of this transaction and other recently announced transactions, Valeant is well on its way to being one of the leading companies in dermatology," stated J. Michael Pearson, chairman and chief executive officer. "We believe that dermatology remains an attractive therapeutic area for Valeant and we are pleased to able to add another strong franchise to our growing operations."

 

SEE RELATED STORIES FROM THE WDM CONTENT NETWORK:

Click here to read the latest issue of Business Review Canada

 

Part of Ortho’s portfolio RETIN-A MICRO is a prescription-strength acne treatment mainly used by teens. Advertised as a treatment that clears skin in approximately two weeks and with around seven showing full results.

Clearly in a move to progress further dermatology solutions, this announcement from Valeant comes just after a similar announcement of an acquisition of Dermik, another dermatology specialization company.

Valeant Pharmaceuticals International is a Mississauga, Ontario based company that advertises itself as a “multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas neurology, dermatology, and branded generics.”

Share

Featured Articles

Amelia DeLuca, CSO at Delta Air Lines on Female Leadership

Driving decarbonisation at Delta Air Lines, Chief Sustainability Officer Amelia DeLuca discusses the rise of the CSO and value of more women in leadership

Liz Elting – Driving Equality & Building Billion-$ Business

Founder and CEO Liz Elting Turned Her Passion into Purpose and Created a Billion-Dollar Business While Fighting for Workplace Equality – and Winning

JPMorgan Chase: Committed to supporting the next generation

JPMorgan has unveiled a host of new and expanded philanthropic activities totalling US$3.5 million to support the development of apprenticeship programmes

How efficient digital ecosystems became business critical

Technology & AI

Mastercard: Supporting clients at a time of rapid evolution

Digital Strategy

Why Ceridian has boldly rebranded to Dayforce

Human Capital